Replies to post #62544 on Decision Diagnostics Corp (DECN)

[nonsequetor]

GenViro! provides results in 15 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19. Our method is quicker, provides the desired result, is much cheaper, and effective."

[rawman]

TALK ABOUT A SAY NOTHING PR!!!!

Here is the only notable takeaway:

March 23 -- Today, DECN announces that the company, through its advanced development team in Korea, have finalized the configuration of the GenViro! Swift Kit test strip that will go into production just as soon as the FDA grants emergency status to the DECN product.

>>>"finalized the configuration" -- per the earlier PR's the configuration had already been finalized and DECN was hoping to gain access to the infected Korean blood samples for testing. Hmmmm....?

>>>"will go into production" -- where? DECN does not have a commercial manufacturing facility.

>>>"product testing" -- not mentioned!!!

>>>"as soon as the FDA grants emergency status" -- it ain't gonna happen without a substantial amount of valid test data, which will take time to produce and summarize. Keep in mind, per Berman, the product configuration has just been finalized!

It appears CEO Keith Berman is the "Master of Headlines", but the actual meat is lacking!

BTW, the PR very clearly documents the FACT the DECN blood testing technology is NOT included as a part of the FDA EUA Guidelines. Per the FDA mandate, Mr. Berman should hookup with the FDA to "discuss" it!